New advances in lung cancer chemotherapy: Topotecan and the role of topoisomerase I inhibitors

Oncology

Volumn 61, Issue SUPPL. 1, 2001, Pages 14-24

  Huang, Chao Hui ^a   Treat, Joseph ^a  

^a TEMPLE UNIVERSITY HEALTH SYSTEM   (United States)

Author keywords

Chemotherapy; Inhibitors; Lung cancer; Topoisomerase I; Topotecan

Indexed keywords

AMSACRINE; ANTIMETABOLITE; BLEOMYCIN; CAMPTOTHECIN; CARBOPLATIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE; DNA TOPOISOMERASE INHIBITOR; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; GYRASE INHIBITOR; IRINOTECAN; NAVELBINE; PACLITAXEL; TAXANE DERIVATIVE; TOPOTECAN; VINBLASTINE; VINCA ALKALOID; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CARDIOTOXICITY; CELL DEATH; CLINICAL TRIAL; CONFERENCE PAPER; COVALENT BOND; CROSS RESISTANCE; DNA REPLICATION; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG DNA INTERACTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG PENETRATION; DRUG TOLERABILITY; ENZYME INHIBITION; HEMORRHAGIC CYSTITIS; HUMAN; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; SIDE EFFECT; STEADY STATE; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0035742059     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000055387     Document Type: Conference Paper

References (74)

1. New chemotherapy agents for small cell lung cancer
2. Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: A study of the Eastern Cooperative Oncology Group
3. Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. Adopted on May 16, 1997 by the American Society of Clinical Oncology
4. Taxol stabilizes microtubules in mouse fibroblast cells
5. Phase II study of paclitaxel in patients with extensive-disease small-cell lung cancer: An Eastern Cooperative Oncology Group study
6. A phase II trial of Taxol and GCSF in previously untreated patients with extensive stage small cell lung cancer (SCLC)
7. Phase III trial comparing etoposide (E), cisplatin (C) versus Taxol (T) with cisplatin-G-CSF versus Taxol-cisplatin in advanced non-small cell lung cancer. An Eastern Cooperative Oncology Group (ECOG) trial
8. Phase III comparative study of high-dose cisplatin (HD-CIS) versus a combination of paclitaxel (TAX) and cisplatin (CIS) in patients with advanced non-small cell lung cancer (NSCLC)
9. Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer
10. The role of new agents in advanced non-small-cell lung carcinoma
11. Comparison of the aneugenic effect of vinorelbine and vincristine in cultured human lymphocytes
12. Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: A phase II study
13. Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: A phase II study
14. Gemcitabine is an active new agent in previously untreated extensive small cell lung cancer (SCLC). A study of the National Cancer Institute of Canada Clinical Trials Group
15. Gemcitabine: Metabolism, mechanisms of action, and self-potentiation
16. Cellular elimination of 2′,2′-difluorodeoxycytidine 5′-triphosphate: A mechanism of self-potentiation
17. Mechanism of action of antitumor drug etoposide: A review
18. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: A phase III trial of the Southeastern Cancer Study Group
19. Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer
20. Topotecan - A novel topoisomerase I inhibitor: Pharmacology and clinical experience
21. Topoisomerase I inhibitors: Topotecan and irinotecan
22. Topoisomerase inhibitors. A review of their therapeutic potential in cancer
23. DNA topoisomerases
24. Human DNA topoisomerase I is encoded by a single-copy gene that maps to chromosome region 20q12-13.2
25. DNA topoisomerase I-targeting drugs as radiation sensitizers
26. DNA topoisomerases: Essential enzymes and lethal targets
27. Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): Correlation with preclinical studies
28. Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer
29. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I
30. Pharmacodynamics of topoisomerase I inhibition: Western blot determination of topoisomerase I and cleavable complex in patients with upper gastrointestinal malignancies treated with topotecan
31. Involvement of nucleic acid synthesis in cell killing mechanisms of topoisomerase poisons
32. Camptothecin derivatives induce regression of human ovarian carcinomas grown in nude mice and distinguish between non-tumorigenic and tumorigenic cells in vitro
33. Design of topoisomerase inhibitors to overcome MDR1-mediated drug resistance
34. Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: Evidence for a specific receptor site and a relation to antitumor activity
35. Topoisomerase I inhibitors: Review and update
36. Cytotoxic activity of topotecan in human tumour cell lines and primary cultures of human tumour cells from patients
37. Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units in vitro
38. Characterisation of a human small-cell lung cancer cell line resistant to the DNA topoisomerase I-directed drug topotecan
39. Interaction of ionizing radiation with topotecan in two human tumor cell lines
40. Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue
41. Reduced cellular accumulation of topotecan: A novel mechanism of resistance in a human ovarian cancer cell line
42. In vitro and in vivo effects of clinically important camptothecin analogues on multidrug-resistant cells
43. Antiangiogenic effects of camptothecin analogues 9-amino-20(S)-camptothecin, topotecan, and CPT-11 studied in the mouse cornea model
44. Clinical pharmacokinetics of topotecan
45. Phase I pharmacokinetics study of topotecan, a new topoisomerase I inhibitor
46. Bioavailability and pharmacokinetics of oral topotecan: A new topoisomerase I inhibitor
47. 14C-TOPO) following systemic administration to rats intracranial (IC) malignant brain tumors
48. A phase I clinical and pharmacokinetic study of the topoisomerase I inhibitor topotecan (SK&F 104864) given as an intravenous bolus every 21 days
49. Phase I clinical and pharmacologic study of topotecan (TOP) in patients with hepatic or renal dysfunction
50. Phase I pharmacologic studies of topotecan in patients with impaired hepatic function
51. Topotecan (T) as second-line therapy in patients (Pts) with small cell lung cancer (SCLC): A phase II study
52. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: A phase II study in patients with refractory and sensitive disease
53. Topotecan (Hycamtin™) in small cell lung cancer (SCLC) after failure of first line therapy: Multicentre phase II study
54. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer
55. Topotecan: A review of its efficacy in small cell lung cancer
56. Cyclophosphamide, doxorubicin, and vincristine in etoposide- and cisplatin-resistant small cell lung cancer
57. Cyclophosphamide, doxorubicin and vincristine with amphotericin B in sonicated liposomes as salvage therapy for small cell lung cancer
58. Five days of oral topotecan (Hycamtin), a phase I and pharmacological study in adult patients with solid tumours
59. Combination chemotherapy with cisplatin and topotecan as second-line treatment of sensitive (S) and refractory (R) small cell lung cancer (SCLC): An EORTC LCCG phase II study
60. Topotecan and paclitaxel, an active couplet in untreated extensive disease small cell lung cancer
61. Phase I trial of paclitaxel, carboplatin, and topotecan with or without filgrastim (granulocyte-colony stimulating factor) in the treatment of patients with advanced, refractory cancer
62. Cisplatin-topotecan-paclitaxel weekly administration with G-CSF support for ovarian and small-cell lung cancer patients: A dose-finding study
63. Synergistic cell killing by ionizing radiation and topoisomerase I inhibitor topotecan (SK&F 104864)
64. Small-cell lung cancer: Treatment progress and prospects
65. A randomized trial of the four most active regimens for metastatic non-small-cell lung cancer
66. Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: A phase II toxicity, response, and survival analysis
67. A randomized phase III trial of four chemotherapy regimens in advanced non-small cell lung cancer (NSCLC)
68. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: Results of an Eastern Cooperative Oncology Group trial
69. Topotecan in the treatment of non-small cell lung cancer
70. Phase II study of topotecan in metastatic non-small-cell lung cancer
71. Phase II study of topotecan in patients with advanced non-small-cell lung cancer previously untreated with chemotherapy
72. A randomized phase II trial of two schedules of topotecan for the treatment of advanced stage non-small cell lung cancer
73. Phase II trial of topotecan administered as a 21-day continuous infusion in previously untreated patients with stage IIIB and IV non-small-cell lung cancer
74. Phase II study of oral topotecan in advanced non-small cell lung cancer